

Regulatory Compliance Testing

ANALYZED BY:

Anresco Laboratories 1375 Van Dyke Avenue, San Francisco, CA 94124 C8-0000052-LIC



DISTR	RIBUTOR:
-------	-----------------

Metta Medical

C11-0001250-LIC

CULTIVATOR / MANUFACTURER:

Metta Medical

	SAMPLE INFOR	SAMPLE INFORMATION					
An and a second se	Product Name: Matrix: Batch #: Product	25HT2102 Concentra Consumec 25HT2102	te (Orally l Concentrate)	Sample Increments: Sample Weight / Increment (g): Total Sample Weight (g): Date Collected: Date Received: Date Reported:	32 1.75 56 03/09/2021 03/10/2021 03/12/2021		
BORATORIES since 1843	TEST SUMMAR Cannabinoid Profil Pesticides Residue Heavy Metals Scree Other Analyses:	le: Screen:	 Pass Pass Pass Pass Pass 	Microbiological Screen: Residual Solvent Screen: Mycotoxins Screen: Overall:	 Pass Pass Pass Pass Pass 		

CANNABINOID PROFILE O Pass

Method:	MF12D012
Instrument:	Liquid Chromatography Diode Array Detector (LC-DAD)
Limit of Quantitation	0.4 mg/g
Limit of Detection	0.1332 mg/g

Cannabinoid	mg/g	%	mg/serving	mg/package	Status
Δ8-THC	ND	ND	ND	ND	-
∆9-THC	152.95	15.295	26.89	268.89	-
Δ9-THCA	ND	ND	ND	ND	-
THCV	0.96	0.097	0.17	1.70	-
THCVA	ND	ND	ND	ND	-
CBD	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td></loq<>	-
CBDA	ND	ND	ND	ND	-
CBC	2.31	0.231	0.41	4.05	-
CBCA	ND	ND	ND	ND	-
CBDV	ND	ND	ND	ND	-
CBG	6.28	0.628	1.10	11.05	-
CBGA	ND	ND	ND	ND	-
CBN	3.29	0.330	0.58	5.79	-
Total THC	152.95	15.295	26.89	268.89	Pass
Total CBD	ND	ND	ND	ND	-
Total Cannabinoids	165.80	16.580	29.15	291.48	-
Total Active Cannabinoids	165.80	16.580	29.15	291.48	-
Serving Weight (g)	0.1758				

MICROBIOLOGICAL SCREEN Ø Pass

Analyte	Method	Findings	Status
Salmonella	AOAC 2016.01	Negative/1g	Pass
STEC	3M MDS STEC/EAE	Negative/1g	Pass

PESTICIDES RESIDUE SCREEN O Pass

Method: MF 21P030

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
0.04/0.10	ND	0.3	Pass
0.04/0.10	ND	5.0	Pass
0.04/0.10	ND	4.0	Pass
0.04/0.10	ND	5.0	Pass
0.04/0.10	ND	0.04	Pass
0.04/0.10	ND	40.0	Pass
	0.04/0.10 0.04/0.10 0.04/0.10 0.04/0.10 0.04/0.10	0.04/0.10 ND 0.04/0.10 ND 0.04/0.10 ND 0.04/0.10 ND 0.04/0.10 ND 0.04/0.10 ND	0.04/0.10 ND 0.3 0.04/0.10 ND 5.0 0.04/0.10 ND 4.0 0.04/0.10 ND 5.0 0.04/0.10 ND 5.0 0.04/0.10 ND 5.0 0.04/0.10 ND 0.04

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124 Sample #: 1075734 Batch #: 25HT210217d9S page **1** of **3**

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.

03/12/2021

03/12/2021

03/12/2021



Regulatory Compliance Testing

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Bifenazate	0.04/0.10	ND	5.0	Pass
Bifenthrin	0.20/0.50	ND	0.5	Pass
Boscalid	0.04/0.10	ND	10.0	Pass
Captan	0.25/0.70	ND	5.0	Pass
Carbaryl	0.20/0.50	ND	0.5	Pass
Carbofuran	0.04/0.10	ND	0.04	Pass
Chlorantraniliprole	0.04/0.10	ND	40.0	Pass
Chlordane	0.04/0.10	ND	0.04	Pass
Chlorfenapyr	0.04/0.10	ND	0.04	Pass
Chlorpyrifos	0.04/0.10	ND	0.04	Pass
Clofentezine	0.04/0.10	ND	0.5	Pass
Coumaphos	0.04/0.10	ND	0.04	Pass
Cyfluthrin	0.70/2.00	ND	1.0	Pass
Cypermethrin	0.35/1.00	ND	1.0	Pass
Daminozide	0.04/0.10	ND	0.04	Pass
DDVP (Dichlorvous)	0.04/0.10	ND	0.04	Pass
Diazinon	0.04/0.10	ND	0.2	Pass
Dimethoate	0.04/0.10	ND	0.04	Pass
Dimethomorph	0.04/0.10	ND	20.0	Pass
Ethoprop(hos)	0.04/0.10	ND	0.04	Pass
Etofenprox	0.04/0.10	ND	0.04	Pass
Etoxazole	0.04/0.10	ND	1.5	Pass
Fenhexamid	0.04/0.10	ND	10.0	Pass
Fenoxycarb	0.04/0.10	ND	0.04	Pass
Fenpyroximate	0.04/0.10	ND	2.0	Pass
Fipronil	0.04/0.10	ND	0.04	Pass
Flonicamid	0.04/0.10	ND	2.0	Pass
Fludioxanil	0.04/0.10	ND	30.0	Pass
Hexythiazox	0.04/0.10	ND	2.0	Pass
Imazalil	0.04/0.10	ND	0.04	Pass
Imidacloprid	0.04/0.10	ND	3.0	Pass
Kresoxim Methyl	0.04/0.10	ND	1.0	Pass
Malathion	0.20/0.50	ND	5.0	Pass
Metalaxyl	0.04/0.10	ND	15.0	Pass
Methiocarb	0.04/0.10	ND	0.04	Pass
Methomyl	0.04/0.10	ND	0.1	Pass
Methyl parathion	0.04/0.10	ND	0.04	Pass
Mevinphos	0.04/0.10	ND	0.04	Pass
Myclobutanil	0.04/0.10	ND	9.0	Pass
Naled	0.04/0.10	ND	0.5	Pass
Oxamyl	0.04/0.10	ND	0.2	Pass
Paclobutrazol	0.04/0.10	ND	0.04	Pass
Pentachloronitrobenzene	0.04/0.10	ND	0.2	Pass
Permethrins	0.20/0.50	ND	20.0	Pass
Phosmet	0.04/0.10	ND	0.2	Pass
Piperonyl Butoxide	0.04/0.10	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.04/0.10	ND	20.0	Pass
Propoxur	0.04/0.10	ND	0.04	Pass
Pyrethrins	0.20/0.50	ND	1.0	Pass
Pyridaben	0.04/0.10	ND	3.0	Pass
Spinetoram	0.04/0.10	ND	3.0	Pass
Spinosad	0.04/0.10	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.04/0.10	ND	13.0	Pass
Spiroxamine	0.04/0.10	ND	0.04	Pass
Tebuconazole	0.04/0.10	ND	2.0	Pass
Thiaclorprid	0.04/0.10	ND	0.04	Pass
Thiamethoxam	0.35/1.00	ND	4.5	Pass
Trifloxystrobin	0.04/0.10	ND	30.0	Pass
	0.070.10		50.0	1 000

RESIDUAL SOLVENT SCREEN O Pass

Method: USP OVI<467>

Instrument: Gas Chromatography Mass Spectrometry (GC/MS)

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.10/1.00	ND	1	Pass
Acetone	50/150	ND	5000	Pass
Acetonitrile	4/12	ND	410	Pass

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124 Sample #: 1075734 Batch #: 25HT210217d9S page **2** of **3**

03/12/2021

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.



Regulatory Compliance Testing

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Benzene	0.10/1.00	ND	1	Pass
n-Butane	48/160	ND	5000	Pass
Chloroform	0.10/1.00	ND	1	Pass
Ethanol	67/200	ND	5000	Pass
Ethyl acetate	27/80	ND	5000	Pass
Ethyl ether	17/50	ND	5000	Pass
Ethylene oxide	0.50/1.00	ND	1	Pass
n-Heptane	1/4	ND	5000	Pass
n-Hexane	2/10	ND	290	Pass
Isopropyl alcohol	33/100	ND	5000	Pass
Methanol	50/150	ND	3000	Pass
Methylene chloride	0.50/1.00	ND	1	Pass
n-Pentane	2/6	ND	5000	Pass
Propane	10/33	ND	5000	Pass
Toluene	10/30	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	30/90	ND	2170	Pass
Trichloroethylene	0.10/1.00	ND	1	Pass

HEAVY METALS SCREEN 🔗 Pass

03/11/2021

03/12/2021

03/11/2021

Method: MF 24E020

Instrument: Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.05	ND	0.5	Pass

MYCOTOXINS SCREEN SPass

Method: MF 21P030

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Analyte	LOD/LOQ (µg/kg)	Findings (µg/kg)	Limit (µg/kg)	Status
Aflatoxin B1	1/5	ND	-	-
Afalatoxin B2	1/5	ND	-	-
Aflatoxin G1	1/5	ND	-	-
Aflatoxin G2	1/5	ND	-	-
Total Aflatoxins	10/20	ND	20	Pass
Ochratoxin A	10/20	ND	20	Pass

OTHER ANALYSES OTHER ANALYSES

Analyte Method Instrument Findings Limit Status Sand, Soils, Cinders, and Visual ND 25% Pass Dirt Mold Visual ND 25% Pass Imbedded Foreign Material Visual ND 25% Pass Insect Fragment Visual ND 1 per 3g Pass Hair Visual ND 1 per 3g Pass Mammalian Excreta Visual ND 1 per 3g Pass Water Activity MF 14G051 Decagon 0.37 0.85 Pass

(-) = Not Tested, ND = None Detected, <LOQ = Below Limit of Quantitation, LOD = Limit of Detection

All LQC samples were performed and met the prescribed acceptance criteria in 16 CCR section 5730, pursuant to 16 CCR section 5726(e)(13)

Reported by



Lab Co Director March 12, 2021



Scan to verify

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124 Sample #: 1075734 Batch #: 25HT210217d9S page 3 of 3

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.